Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged >/=50 Years. (academic.oup.com)

Authors: Goswami J … Das R Journal: Clinical Infectious Diseases Published: 2026-04-30 DOI: https://doi.org/10.1093/cid/ciaf515